Ulrich-Peter Rohr

Ulrich-Peter Rohr

Auto-generated profile, based on publicly available information

Ulrich-Peter Rohr

Swissmedic, Swiss Agency for Therapeutic Products, Bern, Switzerland

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2023 in Annals of Internal Medicine
Verified
Journal Article
Closed access
KVKerstin N. Vokinger
Kerstin N. Vokinger
MSMiquel Serra-Burriel
Miquel Serra-Burriel
CGCamille E.G. Glaus
Camille E.G. Glaus
URUlrich-Peter Rohr
Ulrich-Peter Rohr
THThomas J. Hwang
Thomas J. Hwang
AKAaron S. Kesselheim
Aaron S. Kesselheim
The speed of drug regulatory agencies in the United States and Europe is often a source of discussion. The objective of this research was to assess regulatory review duration of first and supplementary indications approved between 2011 and 2020 in the United States and Europe (European Union [EU] and Switzerland) and differences in submission times between the United States and Europe. Descriptive statistics were applied to review times between the jurisdictions and across the therapeutic areas. A regression analysis was done to estimate the association between approval agency and review times. The primary analysis cohort included 241 drugs approved in the United States, the EU, and Switzerland. Of these, 128 drugs had supplemental indications (331 in total) in the United States and 87 had supplemental indications (206 in total) in the EU. Overall median review duration from submission to approval subtracting the clock stop period was 39 weeks in the United States, 44 weeks in the EU, and 44 weeks in Switzerland. When review times within each drug were compared, the European Medicines Agency took a median of 3.7 weeks (IQR, -6.7 to 14.9 weeks) longer than the U.S. Food and Drug Administration and Swissmedic a median of 0.3 weeks (IQR, -10.6 to 15.3 weeks) longer. Median total review duration for supplemental indications was 26 weeks in the United States and 40 weeks in the EU. Applications were submitted a median of 1.3 and 17.9 weeks later in the EU and Switzerland, respectively, than in the United States. The regression analysis showed small differences in submission times between the United States and the EU (-2.1 weeks [95% CI, -11.7 to 7.6 weeks]) and larger differences between the United States and Switzerland (33.0 weeks [CI, 23.1 to 42.8 weeks]). It would be beneficial for patients if differences in submission times between the United States and Europe continue to be minimized.

11 February 2026 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
FPFrancesco Pignatti
Francesco Pignatti
TETarec Christoffer El‐Galaly
Tarec Christoffer El‐Galaly
MKMartin Kaiser
Martin Kaiser
KPKimmo Porkka
Kimmo Porkka
RDRobin Doeswijk
Robin Doeswijk
DPDouwe Postmus
Douwe Postmus
External comparator cohort (ECC) studies with real‐world data (RWD) may provide more reliable estimates of treatment differences compared to single‐arm trials (SAT), yet they face limitations such as selection bias and data heterogeneity. This study assessed the perceived strength of evidence of ECC studies compared to SAT and randomized controlled studies (RCT). The study included healthcare professionals (HCP) from the European Hematology Association (EHA), the European Society for Medical Oncology (ESMO), and assessors from international regulatory agencies (RA). A conjoint analysis evaluated strength of evidence ratings for establishing an effect on OS for different hypothetical scenarios, based on different designs, RWD quality, and observed OS improvement, for a new cancer treatment for advanced disease and no effective treatments. Participants from HCP organizations rated RWD studies favorably (advantages outweigh disadvantages) more frequently (47.6%; n = 103) compared to RA participants (12.9%; n = 116). Compared to a SAT, a high‐quality RWD ECC study showing a 1.5‐month and 3‐month OS improvement had 2.7 (95% CI: 1.9–3.8) and 14.7 (95% CI: 10.0–21.5) times higher odds of receiving a higher strength of evidence rating, respectively. The OR for RCT v. SAT was 36.4 (95% CI: 24.0–55.2) and 358.4 (95% CI: 217.3–591.3), respectively. Strength of evidence ratings were associated with maximum acceptable risk of severe or symptomatic toxicity. In conclusion, when evaluating the OS of new therapies, ECC studies with RWD, especially when based on high‐quality RWD or demonstrating a larger OS benefit, were rated as more convincing than SAT without a formal control.

25 July 2025 in BMJ Connections Oncology
Verified
Journal Article
Open access
PDF file
PRParisa Rahimzadeh
Parisa Rahimzadeh
QLQiyu Li
Qiyu Li
LRLeonie Rudofsky
Leonie Rudofsky
SSSimon Dalla Torre di Sanguinetto
Simon Dalla Torre di Sanguinetto
NMNicola Miglino
Nicola Miglino
AWAndreas Wicki
Andreas Wicki
Introduction: Cancer treatment has advanced rapidly in recent decades. Regulatory approval of cancer therapies relies on pivotal clinical trials, with phase III, randomised controlled trials (RCTs) regarded as the gold standard. However, there is growing concern about the increasing use of single-arm trials in cancer approvals. This study provides an overview of cancer drug approvals in Switzerland over the past 20 years. We assessed changes in approval patterns, characteristics of pivotal trials and the use of biomarkers in approvals. Research design and methods: We collected data on Swiss cancer drug approvals from 2001 to 2020, and their respective pivotal trials from Swissmedic’s internal database and performed descriptive analyses. Results: Over 20 years, Swissmedic approved 362 cancer-related indications, 40.6% as new active substances. Solid tumours accounted for 63.3% of approvals, with lung cancer achieving top ranking with 22.3%. Approvals rose from 6 in 2001 to 34 in 2020, with biomarker-associated indications increasing from 16.7% in 2001 to 55.9% in 2020. Indications were mainly approved based on RCTs (71.3%). However, the proportion of single-arm trials supporting approvals for solid tumours increased from 14.3% in 2005 to 34.6% in 2020, with most approvals covering rare cancer entities and biomarker-associated indications. Conclusions: The notable rise in cancer drug approvals and biomarker-associated indications has expanded treatment options. While RCTs remained the primary basis for approvals, the growing reliance on single-arm trials, specifically for biomarker-associated approvals, introduces uncertainty for regulatory agencies in assessing benefit-risk profiles. This highlights the importance of postapproval evidence generation to confirm long-term safety and efficacy.

1 April 2026 in JCO Oncology Practice
Verified
Journal Article
Closed access
SHSimon Hediger
Simon Hediger
LWLara Welti
Lara Welti
CGCamille E.G. Glaus
Camille E.G. Glaus
URUlrich-Peter Rohr
Ulrich-Peter Rohr
KVKerstin Noelle Vokinger
Kerstin Noelle Vokinger
PURPOSE: The objective of priority review is to expedite the review duration for drugs that provide significant improvements. We analyzed the duration of regulatory review of cancer drugs granted priority versus nonpriority review and differences in the proportion of cancer drugs with high therapeutic value granted priority versus nonpriority review in the United States, European Union, and Switzerland. METHODS: In this cross-sectional study, we used US Food and Drug Administration’s (FDA), European Medicines Agency's (EMA), and Swissmedic's databases to identify all new cancer drugs approved in 2010-2024, their submission and approval dates, and approval pathways. European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) and ESMO-Magnitude of Clinical Benefit Scale for Haematological Malignancies scores were calculated to assess their therapeutic value. We applied summary statistics (medians and IQR) to describe differences in review duration for priority versus nonpriority review. Review duration was calculated from submission to approval date. For estimated differences in proportions of high therapeutic value scores for drugs granted priority versus nonpriority review, we calculated classical normal 95% CIs. RESULTS: In all, 144 (86%) of 168 cancer drugs were granted priority review by the FDA, 37 (25%) of 147 by EMA, and 37 (28%) of 132 by Swissmedic. Of those, the FDA reviewed 30%, EMA 5%, and Swissmedic 49% within the required time period; review duration was similar for drugs with high and low therapeutic value. The difference in the proportion of high value scores between priority and nonpriority review was –4% (95% CI, –20 to 13) for the FDA, 22% (95% CI, 6 to 38) for EMA, and 17% (95% CI, <1 to 33]) for Swissmedic. CONCLUSION: It could be beneficial for patients if agencies applied more scrutiny in the selection of which cancer drugs to grant priority review. Such drugs should have a high therapeutic value, and their review should be completed in a timely manner to enable quicker access to important cancer drugs for patients. Although the FDA would need to take the most substantial steps, EMA and Swissmedic could also improve their systems.